CCL7

Overview

CCL7 (C-C Motif Chemokine Ligand 7; also known as MCP-3) is a monocyte/macrophage chemoattractant chemokine. Together with CCL2, CCL8, and CCL13, elevated CCL7 expression in pretreatment melanoma biopsies marks tumors innately resistant to anti-PD-1 checkpoint immunotherapy, as part of the IPRES (innate anti-PD-1 resistance) transcriptional signature.

Alterations observed in the corpus

• CCL7 was identified as a monocyte/macrophage chemoattractant up-regulated in non-responders to anti-PD-1 therapy in melanoma, part of the IPRES innate resistance transcriptional signature PMID:26997480.

Cancer types (linked)

• SKCM: CCL7 overexpression in pretreatment melanoma biopsies is enriched in tumors that fail to respond to anti-PD-1 therapy; co-upregulated with CCL2, CCL8, CCL13 PMID:26997480.

Co-occurrence and mutual exclusivity

• Co-expressed with CCL2, CCL8, CCL13, VEGFA, VEGFC, IL10, and mesenchymal genes (AXL, ROR2, WNT5A) in IPRES-positive non-responding melanomas PMID:26997480.

Therapeutic relevance

• As a component of the IPRES signature, CCL7 overexpression identifies patients unlikely to respond to anti-PD-1 monotherapy; combination approaches targeting the tumor-associated macrophage microenvironment are a proposed strategy PMID:26997480.

Open questions

• Prospective validation of the IPRES signature (including CCL7) in independent cohorts is required before clinical use as a biomarker PMID:26997480.

Sources

• PMID:26997480

This page was processed by crosslinker on 2026-05-14.